Membrane Proteins

膜蛋白
  • 文章类型: Journal Article
    这项研究通过使用高通量单细胞转录组测序和先进的生物信息学分析研究TRIM28的作用及其复杂的分子机制,深入研究了去势抵抗前列腺癌(CRPC)的未开发领域。我们的全面检查揭示了动态的TRIM28表达变化,特别是在CRPC内的免疫细胞如巨噬细胞和CD8+T细胞中。与TCGA数据的相关性分析强调了TRIM28与免疫检查点表达之间的联系,并强调了其对免疫细胞数量和功能的关键影响。使用TRIM28基因敲除小鼠模型,我们确定了差异表达的基因和富集的途径,揭示TRIM28在cGAS-STING途径中的潜在调控参与。体外,实验进一步说明,前列腺癌细胞中TRIM28基因敲除通过抑制M2巨噬细胞极化和增强CD8+T细胞活性而诱导了显著的抗肿瘤免疫作用。这一有影响力的发现在原位移植肿瘤模型中得到了验证,其中TRIM28基因敲除表现出肿瘤生长的减速,减少M2巨噬细胞的比例,增强CD8+T细胞的浸润。总之,这项研究阐明了迄今为止未知的TRIM28在CRPC中的抗肿瘤免疫作用,并通过cGAS-STING信号通路揭示了其潜在的调节机制。这些发现为CRPC的免疫前景提供了新的见解,为开发创新的治疗策略提供有希望的方向。
    This study delves into the unexplored realm of castration-resistant prostate cancer (CRPC) by investigating the role of TRIM28 and its intricate molecular mechanisms using high-throughput single-cell transcriptome sequencing and advanced bioinformatics analysis. Our comprehensive examination unveiled dynamic TRIM28 expression changes, particularly in immune cells such as macrophages and CD8+ T cells within CRPC. Correlation analyses with TCGA data highlighted the connection between TRIM28 and immune checkpoint expression and emphasized its pivotal influence on the quantity and functionality of immune cells. Using TRIM28 knockout mouse models, we identified differentially expressed genes and enriched pathways, unraveling the potential regulatory involvement of TRIM28 in the cGAS-STING pathway. In vitro, experiments further illuminated that TRIM28 knockout in prostate cancer cells induced a notable anti-tumor immune effect by inhibiting M2 macrophage polarization and enhancing CD8+ T cell activity. This impactful discovery was validated in an in situ transplant tumor model, where TRIM28 knockout exhibited a deceleration in tumor growth, reduced proportions of M2 macrophages, and enhanced infiltration of CD8+ T cells. In summary, this study elucidates the hitherto unknown anti-tumor immune role of TRIM28 in CRPC and unravels its potential regulatory mechanism via the cGAS-STING signaling pathway. These findings provide novel insights into the immune landscape of CRPC, offering promising directions for developing innovative therapeutic strategies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:尿路上皮癌(UC)是第二常见的泌尿系统恶性肿瘤。尽管在过去的几十年中已经评估了许多分子标记,没有用于诊断和复发监测的尿路上皮标志物显示出一致的临床效用.
    方法:分析来自公共数据库和临床收集的组织样本的甲基化水平。纳入患有UC和泌尿系统良性疾病(BUD)的患者,以使用基于限制酶的无亚硫酸氢盐qPCR在训练队列(n=567)中建立TAGMe(甲基化的TAG)评估。在验证队列中进一步验证了TAGMe评估的性能(n=198)。每月收集57例接受术后监测的UC患者的尿液样本,持续六个月,以评估TAGMe甲基化。
    结果:我们确定TAGMe是一种潜在的新型通用仅癌症甲基化(UCOM)标志物,在多类型癌症中被高甲基化,并研究了其在UC中的应用。基于限制性酶的不含亚硫酸氢盐的qPCR用于检测,结果与金标准焦磷酸测序结果一致。重要的是,高甲基化TAGMe在尿液中有效区分UC和BUD患者方面显示出88.9%(95%CI:81.4~94.1%)的良好敏感性和90.0%(95%CI:81.9~95.3%)的特异性,并且在UC的不同临床情况下也表现良好.此外,作为复发指标的TAGMe异常可能先于临床复发3个月至1年,这为及时有效的干预预防UC升级提供了宝贵的时间窗口。
    结论:基于尿液新的单一目标的TAGMe评估在UC诊断和复发监测中是有效且易于执行的,这可以减轻膀胱镜检查的负担。试用注册ChiCTR2100052507。2021年10月30日注册。
    BACKGROUND: Urothelial carcinoma (UC) is the second most common urological malignancy. Despite numerous molecular markers have been evaluated during the past decades, no urothelial markers for diagnosis and recurrence monitoring have shown consistent clinical utility.
    METHODS: The methylation level of tissue samples from public database and clinical collected were analyzed. Patients with UC and benign diseases of the urinary system (BUD) were enrolled to establish TAGMe (TAG of Methylation) assessment in a training cohort (n = 567) using restriction enzyme-based bisulfite-free qPCR. The performance of TAGMe assessment was further verified in the validation cohort (n = 198). Urine samples from 57 UC patients undergoing postoperative surveillance were collected monthly for six months after surgery to assess the TAGMe methylation.
    RESULTS: We identified TAGMe as a potentially novel Universal-Cancer-Only Methylation (UCOM) marker was hypermethylated in multi-type cancers and investigated its application in UC. Restriction enzyme-based bisulfite-free qPCR was used for detection, and the results of which were consistent with gold standard pyrosequencing. Importantly, hypermethylated TAGMe showed excellent sensitivity of 88.9% (95% CI: 81.4-94.1%) and specificity of 90.0% (95% CI: 81.9-95.3%) in efficiently distinguishing UC from BUD patients in urine and also performed well in different clinical scenarios of UC. Moreover, the abnormality of TAGMe as an indicator of recurrence might precede clinical recurrence by three months to one year, which provided an invaluable time window for timely and effective intervention to prevent UC upstaging.
    CONCLUSIONS: TAGMe assessment based on a novel single target in urine is effective and easy to perform in UC diagnosis and recurrence monitoring, which may reduce the burden of cystoscopy. Trial registration ChiCTR2100052507. Registered on 30 October 2021.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    转移性胃癌(GC)由于其预后差和有限的治疗选择而提出了重大的临床挑战。为了解决这个问题,我们进行了一项靶向蛋白质生物标志物发现研究,以鉴定晚期GC(AGC)转移的预测标志物.使用Olink蛋白质组学靶标组分析来自176名AGC患者(T阶段3或更高)的血清样品。患者被回顾性地分类为非转移性,转移性,和复发组,并评估差异蛋白表达。应用机器学习和基因集富集分析(GSEA)方法发现生物标志物并预测预后。四种蛋白质(MUC16,CAIX,5\'-NT,与对照组相比,转移性GC患者的CD8A)显着升高。此外,GSEA表明,转移性患者对白细胞介素4和缺氧相关途径的反应丰富。随机森林分类和决策树模型显示MUC16可能是GC患者转移的预测标志物。此外,ELISA验证证实转移性患者中MUC16水平升高。值得注意的是,高MUC16水平与T3或更高GC的转移进展独立相关.这些发现表明MUC16作为临床相关的生物标志物用于鉴定具有高转移风险的GC患者的潜力。
    Metastatic gastric cancer (GC) presents significant clinical challenges due to its poor prognosis and limited treatment options. To address this, we conducted a targeted protein biomarker discovery study to identify markers predictive of metastasis in advanced GC (AGC). Serum samples from 176 AGC patients (T stage 3 or higher) were analyzed using the Olink Proteomics Target panels. Patients were retrospectively categorized into nonmetastatic, metastatic, and recurrence groups, and differential protein expression was assessed. Machine learning and gene set enrichment analysis (GSEA) methods were applied to discover biomarkers and predict prognosis. Four proteins (MUC16, CAIX, 5\'-NT, and CD8A) were significantly elevated in metastatic GC patients compared to the control group. Additionally, GSEA indicated that the response to interleukin-4 and hypoxia-related pathways were enriched in metastatic patients. Random forest classification and decision-tree modeling showed that MUC16 could be a predictive marker for metastasis in GC patients. Additionally, ELISA validation confirmed elevated MUC16 levels in metastatic patients. Notably, high MUC16 levels were independently associated with metastatic progression in T3 or higher GC. These findings suggest the potential of MUC16 as a clinically relevant biomarker for identifying GC patients at high risk of metastasis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    STING中的功能增益突变导致STING相关的血管病变,在婴儿期(SAVI)发病,其特征是早发性全身性炎症,皮肤血管病变,和间质性肺病.这里,我们报告并描述了在SAVI患者中鉴定的新型STING变体(F269S)。患者骨髓的单细胞转录组学揭示了跨细胞类型的干扰素(IFN)和炎症途径的自发激活,并且观察到循环幼稚T细胞的惊人流行。诱导型STINGF269S表达通过蛋白质的配体非依赖性转运至高尔基体,保护细胞免受病毒感染,但阻止其有效的免疫启动。此外,SAVI免疫细胞分泌细胞因子可促进并进一步加剧内皮细胞活化,导致炎症和内皮损伤。我们的研究发现STINGF269S突变是导致SAVI的一种新的致病变异,强调内皮细胞和免疫细胞之间的串扰在肺部疾病中的重要性,并有助于更好地理解异常STING激活如何引起病理。
    Gain-of-function mutations in STING cause STING-associated vasculopathy with onset in infancy (SAVI) characterized by early-onset systemic inflammation, skin vasculopathy, and interstitial lung disease. Here, we report and characterize a novel STING variant (F269S) identified in a SAVI patient. Single-cell transcriptomics of patient bone marrow revealed spontaneous activation of interferon (IFN) and inflammatory pathways across cell types and a striking prevalence of circulating naïve T cells was observed. Inducible STING F269S expression conferred enhanced signaling through ligand-independent translocation of the protein to the Golgi, protecting cells from viral infections but preventing their efficient immune priming. Additionally, endothelial cell activation was promoted and further exacerbated by cytokine secretion by SAVI immune cells, resulting in inflammation and endothelial damage. Our findings identify STING F269S mutation as a novel pathogenic variant causing SAVI, highlight the importance of the crosstalk between endothelial and immune cells in the context of lung disease, and contribute to a better understanding of how aberrant STING activation can cause pathology.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    过氧化物酶体是执行多种代谢功能的多功能细胞器。PEX3,过氧化物酶体的关键调节剂,参与与过氧化物酶体相关的各种生物过程。PEX3是否参与过氧化物酶体相关的氧化还原稳态和心肌再生修复仍然难以捉摸。我们研究了心肌细胞特异性PEX3敲除(Pex3-KO)导致氧化还原稳态失衡,并破坏了不同时间和空间位置的内源性增殖/发育。使用Pex3-KO小鼠和心肌靶向干预方法,探讨了PEX3在生理和病理阶段对心肌再生修复的影响。机械上,脂质代谢组学显示PEX3通过影响缩醛磷脂代谢促进心肌再生修复。Further,我们发现PEX3调节的缩醛磷脂通过ITGB3的质膜定位激活AKT/GSK3β信号通路。我们的研究表明,PEX3可能是损伤后心肌再生修复的新治疗靶标。
    The peroxisome is a versatile organelle that performs diverse metabolic functions. PEX3, a critical regulator of the peroxisome, participates in various biological processes associated with the peroxisome. Whether PEX3 is involved in peroxisome-related redox homeostasis and myocardial regenerative repair remains elusive. We investigate that cardiomyocyte-specific PEX3 knockout (Pex3-KO) results in an imbalance of redox homeostasis and disrupts the endogenous proliferation/development at different times and spatial locations. Using Pex3-KO mice and myocardium-targeted intervention approaches, the effects of PEX3 on myocardial regenerative repair during both physiological and pathological stages are explored. Mechanistically, lipid metabolomics reveals that PEX3 promotes myocardial regenerative repair by affecting plasmalogen metabolism. Further, we find that PEX3-regulated plasmalogen activates the AKT/GSK3β signaling pathway via the plasma membrane localization of ITGB3. Our study indicates that PEX3 may represent a novel therapeutic target for myocardial regenerative repair following injury.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    使用70U/ml或35U/ml作为CA125常规异常阈值可能导致卵巢癌(OvCa)复发检测的遗漏。这项研究旨在阐明生化复发(仅CA125升高)与影像识别复发之间的关联,以更好地预测复发病变。162名获得完全临床反应的患者来自诊断为I-IV期浆液性卵巢的女性,输卵管,和腹膜癌2013年1月至2019年6月在我们中心。2×最低点的CA125水平被定义为图像识别复发的指标(P<0.001)。与超过35U/ml的CA125水平相比,CA125的2倍最低点提高了图像识别复发的敏感性(84.9%vs67.4%,P<0.001);2×最低点值可以作为较早的警告复发信号,图像识别复发的中位时间更长(2.7vs.0个月,P<0.001)。在复发的人群中,初始治疗后,新辅助化疗(NACT)和原发性减瘤手术(PDS)组的CA125变化趋势无差异。与35U/ml相比,在浆液性OvCa患者中,CA125在随访过程中达到2×最低点可能是更敏感和早期复发的信号。该标准可以帮助指导患者被推荐进行影像学检查以及时发现潜在的复发。
    Using 70 U/ml or 35 U/ml as CA125 routine abnormal threshold may result in omissions in the relapse detection of Ovarian cancer (OvCa). This study aimed to clarify the association between a biochemical relapse (only the elevation of CA125) and an image-identified relapse to predict the relapsed lesions better. 162 patients who achieved complete clinical response were enrolled from women diagnosed with stage I-IV serous ovarian, tubal, and peritoneal cancers from January 2013 to June 2019 at our center. The CA125 level of 2 × nadir was defined as the indicator of image-identified relapse (P < 0.001). Compared to CA125 level exceeding 35 U/ml, the 2 × nadir of CA125 improve the sensitivity of image-identified relapse (84.9% vs 67.4%, P < 0.001); the 2 × nadir value can act as an earlier warning relapse signal with a longer median time to image-identified relapse (2.7 vs. 0 months, P < 0.001). Of the relapsed population, there was no difference of CA125 changing trend between the neoadjuvant chemotherapy (NACT) and primary debulking surgery (PDS) group after initial treatment. Compared with 35 U/ml, CA125 reaching 2 × nadir during the follow-up process might be a more sensitive and early relapse signal in patients with serous OvCa. This criterion may help guide patients to be recommended for imaging examination to detect potential relapse in time.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    根据单分子定位显微镜,几乎所有的质膜蛋白质都成簇。我们证明了簇可以起因于膜形貌的变化,其中随机分布的膜分子的局部密度在一定程度上与膜的局部量的变化相匹配。Further,我们证明,通过使用膜标记报告膜数量的局部变化,可以将这种错误的聚类与真正的聚类区分开来。在使用膜探针DiI以及转铁蛋白受体或GPI锚定蛋白CD59的双色活细胞单分子定位显微镜中,我们发现配对相关分析报告蛋白质和DiI均成簇,其衍生对相关-光活化定位显微镜和最近邻分析也是如此。在将定位转换为图像并使用DiI图像来分解地形变化之后,没有可见的CD59簇,这表明其他方法报告的聚类是一种假象。然而,在排除地形变化后,TfR簇仍然存在。我们证明了膜形貌的变化可以使膜分子看起来成簇,并提出了一种直接的补救措施,适合作为聚类分析流程的第一步。
    According to single-molecule localisation microscopy almost all plasma membrane proteins are clustered. We demonstrate that clusters can arise from variations in membrane topography where the local density of a randomly distributed membrane molecule to a degree matches the variations in the local amount of membrane. Further, we demonstrate that this false clustering can be differentiated from genuine clustering by using a membrane marker to report on local variations in the amount of membrane. In dual colour live cell single molecule localisation microscopy using the membrane probe DiI alongside either the transferrin receptor or the GPI-anchored protein CD59, we found that pair correlation analysis reported both proteins and DiI as being clustered, as did its derivative pair correlation-photoactivation localisation microscopy and nearest neighbour analyses. After converting the localisations into images and using the DiI image to factor out topography variations, no CD59 clusters were visible, suggesting that the clustering reported by the other methods is an artefact. However, the TfR clusters persisted after topography variations were factored out. We demonstrate that membrane topography variations can make membrane molecules appear clustered and present a straightforward remedy suitable as the first step in the cluster analysis pipeline.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    Wolfram综合征1(WS1)是一种罕见的,以尿崩症为特征的常染色体隐性神经退行性疾病,胰岛素依赖型糖尿病,视神经萎缩,和由WFS1基因功能丧失遗传变异导致的耳聋。患有WS1的个体表现出一系列神经精神疾病。这里,我们报道了一例WS1的儿科病例,该病例源于一种新的双等位基因WFS1功能丧失遗传变异.最初表现为强迫症的个体,由氟伏沙明成功管理。两个月后,孩子表现出白天过度嗜睡。临床评估和睡眠记录显示诊断为2型发作性睡病。哌醋甲酯改善了白天过度嗜睡。据我们所知,这是WS1发作性睡病的首例报道,发作性睡病可能发生在进行性神经退行性过程中.我们强调需要深入筛查WS1的神经精神表型和睡眠相关疾病,以进行临床管理,这显著提高了生活质量。
    UNASSIGNED: Wolfram syndrome 1 (WS1) is a rare, autosomal recessive neurodegenerative disorder characterized by diabetes insipidus, insulin-dependent diabetes mellitus, optic atrophy, and deafness resulting from loss-of-function genetic variants in the WFS1 gene. Individuals with WS1 manifest a spectrum of neuropsychiatric disorders. Here, we report a pediatric case of WS1, which stemmed from a novel biallelic WFS1 loss-of-function genetic variant. The individual initially presented with obsessive-compulsive disorder, which was successfully managed by fluvoxamine. After 2 months, the child manifested excessive daytime sleepiness. Clinical evaluation and sleep recordings revealed a diagnosis of narcolepsy type 2. Excessive daytime sleepiness was improved with methylphenidate. To the best of our knowledge, this is the first report of narcolepsy in WS1, which possibly arose during a progressive neurodegenerative process. We emphasize the need for in-depth screening for neuropsychiatric phenotypes and sleep-related disorders in WS1, for clinical management, which significantly improves the quality of life.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    原理:已知自噬失调是多柔比星(DOX)诱导的心脏毒性(DIC)的机制。线粒体-内质网接触(MERC)是自噬启动和自噬体形成的地方。然而,MERC在DIC自噬失调中的作用仍然难以捉摸。FUNDC1是MERC的系链蛋白。我们旨在研究DOX对心肌细胞MERC的影响,并探讨其是否参与DIC中自噬失调。方法:我们采用共聚焦显微镜和透射电子显微镜来评估MERC的结构。使用mCherry-EGFP-LC3B荧光测定和针对LC3BII的蛋白质印迹分析自噬通量。通过mCherry-EGFP-FIS1荧光测定和LC3B与线粒体之间的共定位分析研究了线粒体自噬。在小鼠中施用18mg/kg的总剂量的多柔比星以构建体内DIC模型。此外,我们使用腺相关病毒(AAV)在心脏特异性过度表达FUNDC1.通过超声心动图和Masson三色染色评估心功能和重塑,分别。结果:DOX通过抑制自噬小体的生物发生阻断自噬通量,这可能归因于FUNDC1的下调和MERC结构的中断。FUNDC1过表达通过维持MERC结构和促进ATG5-ATG12/ATG16L1复合物形成而不改变线粒体自噬来恢复被阻断的自噬体生物发生。此外,FUNDC1以自噬依赖性方式减轻DOX诱导的氧化应激和心肌细胞死亡。值得注意的是,FUNDC1的心脏特异性过表达可保护DOX处理的小鼠免受不良心脏重塑并改善心脏功能。结论:总之,我们的研究发现,由FUNDC1介导的MERC通过恢复被阻断的自噬体生物发生,对DIC具有心脏保护作用.重要的是,这项研究揭示了FUNDC1在DIC模型中通过恢复MERC结构和自噬体生物发生增强巨自噬中的新作用,超出其先前已知的作为线粒体自噬受体的调节作用。
    Rationale: Autophagy dysregulation is known to be a mechanism of doxorubicin (DOX)-induced cardiotoxicity (DIC). Mitochondrial-Endoplasmic Reticulum Contacts (MERCs) are where autophagy initiates and autophagosomes form. However, the role of MERCs in autophagy dysregulation in DIC remains elusive. FUNDC1 is a tethering protein of MERCs. We aim to investigate the effect of DOX on MERCs in cardiomyocytes and explore whether it is involved in the dysregulated autophagy in DIC. Methods: We employed confocal microscopy and transmission electron microscopy to assess MERCs structure. Autophagic flux was analyzed using the mCherry-EGFP-LC3B fluorescence assay and western blotting for LC3BII. Mitophagy was studied through the mCherry-EGFP-FIS1 fluorescence assay and colocalization analysis between LC3B and mitochondria. A total dose of 18 mg/kg of doxorubicin was administrated in mice to construct a DIC model in vivo. Additionally, we used adeno-associated virus (AAV) to cardiac-specifically overexpress FUNDC1. Cardiac function and remodeling were evaluated by echocardiography and Masson\'s trichrome staining, respectively. Results: DOX blocked autophagic flux by inhibiting autophagosome biogenesis, which could be attributed to the downregulation of FUNDC1 and disruption of MERCs structures. FUNDC1 overexpression restored the blocked autophagosome biogenesis by maintaining MERCs structure and facilitating ATG5-ATG12/ATG16L1 complex formation without altering mitophagy. Furthermore, FUNDC1 alleviated DOX-induced oxidative stress and cardiomyocytes deaths in an autophagy-dependent manner. Notably, cardiac-specific overexpression of FUNDC1 protected DOX-treated mice against adverse cardiac remodeling and improved cardiac function. Conclusions: In summary, our study identified that FUNDC1-meditated MERCs exerted a cardioprotective effect against DIC by restoring the blocked autophagosome biogenesis. Importantly, this research reveals a novel role of FUNDC1 in enhancing macroautophagy via restoring MERCs structure and autophagosome biogenesis in the DIC model, beyond its previously known regulatory role as an mitophagy receptor.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    PRL1和PRL3,蛋白酪氨酸磷酸酶家族的成员,已与癌症转移和不良预后有关。尽管对它们的蛋白磷酸酶活性进行了广泛的研究,它们作为脂质磷酸酶的潜在作用仍然难以捉摸。方法:我们进行了全面的调查,以阐明PRL1和PRL3的脂质磷酸酶活性,使用细胞试验的组合,生化分析,和蛋白质相互作用组分析。进行了功能研究以描述PRL1/3对巨细胞增殖的影响及其在癌症生物学中的意义。结果:我们的研究已确定PRL1和PRL3为与磷酸肌醇(PIP)脂质相互作用的脂质磷酸酶,在细胞膜上将PI(3,4)P2和PI(3,5)P2转化为PI(3)P。PRL的这些酶活性促进膜皱褶的形成,膜起泡和随后的巨噬细胞增多,促进营养提取,细胞迁移,和入侵,从而促进肿瘤的发展。PRL的这些酶活性促进膜皱褶的形成,膜起泡和随后的巨噬细胞增多。此外,我们发现PRL1/3的表达与胶质瘤的发展之间存在相关性,提示他们参与了神经胶质瘤的进展。结论:结合已确定PRL参与mTOR的知识,EGFR与自噬,在这里,我们总结了PRL1/3在协调营养传感中的生理作用,通过其脂质磷酸酶活性调节巨细胞作用来吸收和再循环。这种机制可以被面临营养耗尽的微环境的肿瘤细胞利用,强调在癌症治疗中靶向PRL1/3介导的巨噬细胞增多症的潜在治疗意义。
    PRL1 and PRL3, members of the protein tyrosine phosphatase family, have been associated with cancer metastasis and poor prognosis. Despite extensive research on their protein phosphatase activity, their potential role as lipid phosphatases remains elusive. Methods: We conducted comprehensive investigations to elucidate the lipid phosphatase activity of PRL1 and PRL3 using a combination of cellular assays, biochemical analyses, and protein interactome profiling. Functional studies were performed to delineate the impact of PRL1/3 on macropinocytosis and its implications in cancer biology. Results: Our study has identified PRL1 and PRL3 as lipid phosphatases that interact with phosphoinositide (PIP) lipids, converting PI(3,4)P2 and PI(3,5)P2 into PI(3)P on the cellular membranes. These enzymatic activities of PRLs promote the formation of membrane ruffles, membrane blebbing and subsequent macropinocytosis, facilitating nutrient extraction, cell migration, and invasion, thereby contributing to tumor development. These enzymatic activities of PRLs promote the formation of membrane ruffles, membrane blebbing and subsequent macropinocytosis. Additionally, we found a correlation between PRL1/3 expression and glioma development, suggesting their involvement in glioma progression. Conclusions: Combining with the knowledge that PRLs have been identified to be involved in mTOR, EGFR and autophagy, here we concluded the physiological role of PRL1/3 in orchestrating the nutrient sensing, absorbing and recycling via regulating macropinocytosis through its lipid phosphatase activity. This mechanism could be exploited by tumor cells facing a nutrient-depleted microenvironment, highlighting the potential therapeutic significance of targeting PRL1/3-mediated macropinocytosis in cancer treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号